Proteasome activity is frequently enhanced in cancer to accelerate metastasis and tumorigenesis. REGg, a proteasome activator known to promote p53/p21/p16 degradation, is often overexpressed in cancer cells. Here we show that p53/TGF-b signalling inhibits the REGg-20S proteasome pathway by repressing REGg expression. Smad3 and p53 interact on the REGg promoter via the p53RE/SBE region. Conversely, mutant p53 binds to the REGg promoter and recruits p300. Importantly, mutant p53 prevents Smad3/N-CoR complex formation on the REGg promoter, which enhances the activity of the REGg-20S proteasome pathway and contributes to mutant p53 gain of function. Depletion of REGg alters the cellular response to p53/TGF-b signalling in drug resistance, proliferation, cell cycle progression and proteasome activity. Moreover, p53 mutations show a positive correlation with REGg expression in cancer samples. These findings suggest that targeting REGg-20S proteasome for cancer therapy may be applicable to human tumours with abnormal p53/Smad protein status. Furthermore, this study demonstrates a link between p53/TGF-b signalling and the REGg-20S proteasome pathway, and provides insight into the REGg/p53 feedback loop.
R EGg (also known as PA28g, PSME3 or Ki antigen) belongs to the REG or 11S family of proteasome activator that has been shown to bind and activate 20S proteasomes 1, 2 . REGg activates the ubiquitin-independent degradation of steroid receptor coactivator-3 (ref. 3) . In addition, REGg also promotes degradation of several important regulatory proteins, including the cyclindependent kinase inhibitor p21 (refs 4,5) . Moreover, REGg enhances the MDM2-mediated ubiquitination and proteasomal degradation of tumour suppressor p53, inhibiting p53 accumulation and apoptosis after DNA damage 6, 7 . Previous reports showed that REGg-knockout mice and cells displayed reduced growth, decreased cell proliferation and increased apoptosis 8, 9 . Growing evidence suggests that REGg is involved in cancer progression 10 . REGg was reported to be overexpressed in the breast 11 , thyroid 12 , colorectal 13 , lung and liver cancers 14 . However, the molecular mechanisms by which REGg is overexpressed in multiple cancer tissues and cell lines largely remains unknown.
TP53 is a sequence-specific transcription factor, which is present in a very low amount in normal cells. In response to various type of genotoxic stress, p53 is activated to regulate the expression of multiple target genes 15, 16 . The regulation of p53-responsive genes produces proteins that interact with numerous other cellular signalling pathways, and a number of positive and negative autoregulatory feedback loops are generated 17 . The biological implications of these loops mainly depend on the function of the transcriptional targets. Yet, the p53 transcription targets and its feedback loops are not fully understood.
Transforming growth factor-b (TGF-b) is a ubiquitously expressed pleiotropic cytokine that has important roles in cellular function such as apoptosis, cell cycle arrest, homeostasis, immune regulation and angiogenesis 18, 19 . TGF-b is a potent activator of cytostatic programme in epithelial cells 20, 21 . In the classical TGF-b pathway, ligand binding induces the assembly of type I and type II serine/threonine kinase receptors and subsequent phosphorylation of the type I receptor by constitutively active type II receptor [22] [23] [24] . The activated type I receptor phosphorylates cytoplasmic proteins called Smads, thus allowing the formation of heteromeric Smad complexes and their subsequent translocation to the nucleus. Once in the nucleus, these complexes control gene expression through interaction with transcription factors, coactivators and co-repressors 25, 26 . Although TGF-b is considered a double-edged sword for its tumour suppressive and tumour-promoting functions, genetic loss of Smad function through deletion, mutation and subsequent loss of heterozygosity is a frequent event in tumours 27 . It is noteworthy that p53 is known to be required for full activity of TGF-b-mediated regulation by cooperating with Smads 28 . Inactivation of p53 has been linked to alteration of Smad-dependent TGF-b signalling 29 .
Mutation of the p53 tumour suppressor gene is one of the most frequent genetic alterations in human tumours and poses a critical event in tumorigenesis, affecting tumour development, progression and responsiveness to therapy. Approximately 50% of human cancers have p53 loss-of-function mutations 30, 31 . Mutant p53 knockin mice showed a higher frequency of tumour development and increased metastatic potential compared with p53-deficient mice 32, 33 . Tumour-associated forms of mutant p53 can contribute to genomic instability by abrogating the mitotic spindle check point and, consequently, facilitating the generation of aneuploid cells 34, 35 . To date, three molecular mechanisms have been described for gain of function (GOF) of mutant p53: (1) mutant p53 can bind to and inactivate the tumour suppressor proteins such as p63 and p73 (refs 36,37) ; (2) mutant p53 can bind to DNA and control the transcriptional regulation of putative target genes 38, 39 ; and (3) mutant p53 can take part in the formation of large transcriptional competent complexes through which the expression of its target genes is regulated 40, 41 .
Here we report how the REGg-20S proteasome pathway is enhanced during cancer progression. The recruitment of Smad3 and p53 at the intercalated p53RE/Smad-binding element (SBE) region in response to TGF-b provides a convergent action on REGg expression by these tumour suppressive pathways. In addition, REGg overexpression in diverse cancer cell lines can be specifically driven by mutant p53 that is recruited to upstream of the REGg promoter. Moreover, mutant p53 attenuates binding of TGF-b-activated Smad3/4 complex and Nuclear receptor corepressor (N-CoR) to the SBE region of the REGg promoter, highlighting its novel GOF ability. Silencing of REGg alters cellular response to p53 and TGF-b signalling in drug resistance, cell proliferation, 20S proteasome activity and cell cycle progression. Our results demonstrate a role for p53/TGF-b signalling in the regulation of the REGg-20S proteasome pathway, a new GOF for mutant p53 in enhancing the REGg-20S proteasome pathway in cancer cells and further insight into the p53/REGg feedback loop.
Results

TP53 represses REGc via p53RE to generate a feedback loop.
In an effort to analyse transcriptional regulation of REGg, we cloned B2.5 Kb genomic DNA sequences upstream of the REGg translational initiation codon. To define the transcriptional initiation site, we synthesized appropriate primers for REGg and performed 5 0 -RACE (rapid amplification of complementary DNA ends) as described previously 42 . The result indicated that the REGg transcript had a 5 0 -end (defined as þ 1) within 130 bp from the ATG site ( Supplementary Fig. S1a ). When fused to a luciferase reporter, the 2.5-Kb ( À 2,470/ þ 130) and the 1.3-Kb ( À 1,177/ þ 130) untranslated region (UTR) of REGg had similar luciferase activity, whereas the ( À 2,470/ À 1,177) region produced no activity, indicating that the 1.3-Kb ( À 1,177/ þ 130) UTR contains the key regulatory components for transcriptional regulation of REGg ( Supplementary Fig. S1b ). Bioinformatic analysis, using the NCBI database, revealed that the human REGg UTR contains four putative p53 DNA-binding sites 43, 44 (Fig. 1a) . A series of deletion constructs of REGg-luc reporters were generated ( Supplementary Fig. S1c ) for measuring transcriptional activitiy. The derepression in the ( À 518) construct suggested a potential negative regulatory region flanking the ( À 738/ À 518) region, which correlates with the location of p53RE-2 and p53RE-3 ( Supplementary Fig. S1d ).
To investigate whether p53 transcriptionally regulates REGg, we co-transfected the REGg-luc reporter into H1299 cells. Repression was observed when the reporter construct was co-transfected with different doses of p53 (Fig. 1b) . Derepression of REGg also occurred in p53-depleted HCT116 cells ( Supplementary Fig. S2a ). In response to Nutlin-3, inhibition of the REGg transcript was detected in HCT116 (p53 þ / þ ) but not in the isogenic HCT116 (p53 À / À ) cells (Fig. 1c and Supplementary Fig. S2b ). Silencing p53 by short interfering RNA (siRNA) in multiple cancer cells greatly increased REGg mRNA levels compared with controls ( Fig. 1d and Supplementary  Fig. S2c ). Similar to Nutlin-3, cisplatin and etoposide (ETO) also significantly reduced both REGg mRNA and protein expressions (Fig. 1e,f) . Likewise, upregulation of REGg was also observed in p53 À / À mouse embryonic fibroblast cells (Fig. 1g) .
Next, we attempted to identify the regulatory region conferring p53 responsiveness within the REGg promoter. Interestingly, only p53RE-3 displayed strong binding to p53 by electrophoretic mobility shift assay (EMSA; Supplementary Fig. S2d) . Mutation of the p53RE-3 construct abolished its response to p53 inhibition, validating that p53 binds to p53RE-3 to repress REGg transcription (Fig. 1h) . We further confirmed p53 binding to p53RE-3 by EMSA assay, which resulted in the formation of a p53-DNA complex (Fig. 1i, upper panel) . We obtained similar results for the p53RE-3 probe using recombinant p53 protein ( Supplementary  Fig. S2e) . Intriguingly, EMSA analysis also revealed p53 binding to a probe derived from mouse REGg UTR (Fig. 1i, lower panel) .
To determine whether p53 directly binds to p53RE in vivo, a chromatin immunoprecipitation (ChIP) assay was performed using the primers derived from the REGg promoter (Fig. 1j) . The anti-p53 antibody specifically pulled down DNA fragments corresponding to the p53RE-3 region (Fig. 1j , upper two panels and Supplementary Fig. S2f) . Moreover, the ChIP assay also suggested p53 binding to p53RE in the UTR of mouse REGg using mouse embryonic fibroblast cells treated with Nutlin-3 (Fig. 1j, lower panel) . It was previously reported that p53 has been associated with the recruitment of histone deacetylase to repress its target genes 45 . Thus, the ChIP assays also demonstrated a time-course-dependent recruitment of p53 and mSIN3A-HDAC1 co-repressor complex to the REGg promoter (Fig. 1k) . Importantly, this co-repressor complex was preferentially associated with a repressive chromatin status in the REGg promoter, as indicated from the enrichment of Me-H3K9 (Fig. 1k) , a marker of repressed chromatin 46 . Taken together, these data demonstrate that p53 directly binds to the UTR of both human and mouse REGg genes to mediate mSIN3A/HDAC1-dependent transrepression. Given that REGg negatively regulates p53 protein levels, our findings provide a new mechanism for feedback regulation between p53 and REGg pathway in cancer cells.
TGF-b inhibits the REGc-proteasome pathway via Smad complex. As Smad3 and Smad4 specifically recognize the DNA sequence AGAC or GTCT 47 , the presence of multiple SBE in the REGg promoter prompted us to analyse the potential of TGF-b in regulating REGg. In a dose-dependent manner, TGF-b was able to repress the transcriptional activity of the REGg-luc reporter (Fig. 2a) . Ectopic expression of Smad3/4 combination strongly inhibited REGg activity in comparison with Smad2/4 combination (Fig. 2b) . Furthermore, expression of REGg mRNA was also inhibited in response to TGF-b (Fig. 2c , and Supplementary  Fig. S3a ,b). TGF-b was unable to repress REGg in Smad3 knockdown cells (Fig. 2d) . TGF-b treatment also decreased the REGg protein level in multiple cancer cell lines (Fig. 2e) . Similarly, depletion of Smad3 in cancer cells led to the elevated expression of REGg (Fig. 2f) . Next, we sought to define potentially functional SBE in the REGg promoter. We designed oligo probes containing each of the putative SBE, respectively (Fig. 2g) , and found that only SBE-4, but not other SBEs, could have strongly bound to Smad3 (Supplementary Fig. S3c ). Furthermore, formation of the DNA-Smad3/4 complex was observed on SBE-4 ( Fig. 2h) . We also observed the binding of cellular Smads to SBE-4 in response to TGF-b ( Supplementary Fig. S3d ). Moreover, mutation of SBE-4 within the 1.3-Kb REGg-luc reporter blunted its response to TGF-b inhibition, further validating that an activated Smad complex binds to SBE-4 to repress REGg transcription (Fig. 2i) . Finally, we detected recruitment of Smad2/3 and Smad4 to the TGF-b responsive region ( À 796/ À 481; Supplementary  Fig. S3e,f) . Recruitment of Smad proteins to the REGg promoter occurred within 6 h of TGF-b addition and accumulated with increased time of TGF-b treatment (Fig. 2j ). In conclusion, the Smad signalling pathway is required for REGg repression in response to TGF-b, suggesting a potential mechanism by which loss of Smad3 in diverse cancer cells may result in an elevated expression of REGg. Thus, Smad proteins serve as key transcriptional regulators for the REGg-proteasome pathway to maintain low expression of REGg in cancer cells.
p53 and Smad3 interacts via p53RE/SBE in response to TGF-b. Under normal phenotypic conditions, both TGF-b and activated p53 act as gene-specific transcription factors regulating multiple transcriptional targets to achieve tumour suppressive effects 48 . The p53 protein has been identified as a gene-specific partner for Smads and is important for the formation and stabilization of Smad-DNA complexes. Smad2 and Smad3, but not Smad4, directly interact with p53 (ref. 28) . Thus, Smad2/3, bound to TGF-b-responsive element(s), may bridge p53, bound at the p53-binding element, with the Smad complex, allowing additive or synergistic activation of transcription 28, 49 . These hints prompted us to search for intercalated p53RE/SBE site on the REGg promoter.
Intriguingly, we found a p53RE/SBE regulatory region between ( À 565/ À 540) in the REGg promoter, which comprises overlapping p53RE-3/SBE-4 (Fig. 3a) . Expression of either p53 or Smad3/4 with the p53RE/SBE-luc construct repressed reporter activities, whereas these repressions were more dramatic in the presence of TGF-b (Fig. 3b) . Strikingly, coexpression of p53 and Smad3/4 along with TGF-b was significantly more efficient than either p53 or Smad3/4 alone in their regulatory actions (Fig. 3b) . We also obtained similar results for (TA-p63 þ Smad3/4) and (TA-p73 þ Smad3/4) combinations ( Supplementary Fig. S4a,b) . We next verified repression of the REGg gene in A549 cells treated with TGF-b or Nutlin-3, alone or in combination. Either TGF-b or Nutlin-3 can elicit overt inhibition of REGg mRNA levels, whereas this reduction was much more significant when cells were treated with the TGF-b/Nutlin-3 combination (Fig. 3c,d) . Moreover, cosilencing of p53/Smad3 resulted in more than twofold upregulation of REGg expression (Fig. 3e) , indicating that p53 and Smad3/4 act as transcriptional co-repressors on the REGg promoter.
Next, we aimed to address the molecular details of the potential interaction of p53 and Smad proteins at the p53RE-3/SBE-4 region. We silenced Smad3 expression in the A549 cell to determine whether recruitment of p53 to REGg promoter depends on Smad3 in response to TGF-b. ChIP analysis showed no recruitment of Smad3, p53 and N-CoR in Smad3-depleted cells in the presence of TGF-b, which was comparable with control cell lines, suggesting that activated Smad3 interacts with p53 at the p53RE-3/SBE-4 region in response to TGF-b, and entails recruitment of p53 to the REGg promoter (Fig. 3f) . To define binding of these proteins to p53RE-3/SBE-4 regulatory region, we performed an EMSA assay. Incubation of nuclear extracts with a 26-nt probe resulted in formation of a putative p53-Smad-DNA complex, which is enhanced in the presence of TGF-b (Fig. 3g, lanes 2 and 3) . Addition of both antibodies against p53 and Smad3 nearly abolished all bands (Fig. 3g , lane 6), indicating that these complexes contained both p53 and Smad3 proteins. Consistent with our in vitro protein-DNA interaction analysis, ChIP assays revealed that TGF-b stimulated corecruitment of Smad3/p53/N-CoR to this region, suggesting the cooperation between p53 and Smads to further repress REGg (Fig. 3h) . Intriguingly, sequence analysis of the mouse REGg promoter also showed p53RE/SBE site between the ( À 2,939/ À 2,912) region (Fig. 3i) . ChIP assay disclosed binding of Smad3/ p53/N-CoR to this region as well (Fig. 3i) . Next, we depleted expression of N-CoR using specific siRNA to validate the biological impact of N-CoR on REGg regulation. Reverse transcriptase-PCR (RT-PCR) analysis revealed that the REGg mRNA level was elevated in N-CoR knockdown cells (Fig. 3j) . Taken together, our data suggest that synergism/collaboration between p53 and TGF-b occurs on the REGg promoter through the p53RE/SBE region, which contributes to further inhibition of the REGg-proteasome activity. Importantly, our data suggest crosstalk between these two key pathways, not only in human cancer cell lines but also in non-cancer mouse cells.
Mutant p53 interacts and recruits p300 to induce REGc. Mutant p53 was previously detected on the promoters of some target genes, including CD95 (ref. 50 55) , and this was observed in the absence of external stimuli, implying that mutant p53 can directly bind to and regulate its target genes. To understand whether mutant p53 regulate REGg, we co-transfected the REGg-luc reporter with increasing amounts of mutant p53-R175H and observed the dose-dependent transactivation of the REGg-luciferase reporter (Fig. 4a) . Consistently, expressing REGg-luc reporter construct in UMSCC-1 cell lines stably expressing an empty vector, p53 or p53-R175H also suggested a role for mutant p53 to promote REGg transcription ( Supplementary Fig. S5a ). Moreover, all coexpressed constructs containing hotspot p53 mutations significantly activated transcription of REGg reporter in the H1299 cell (Fig. 4b) . To investigate the impact of endogenous mutant p53 on REGg expression, we silenced mutant p53 in multiple cancer cells. Depletion of mutant p53 in these cells reduced the level of REGg transcripts and proteins (Fig. 4c,d , and Supplementary Fig. S5b ,c). mutant p53. The 1.39Kb REGg-luc reporter construct ( À 1,177/ þ 130) was responsive to mutant p53 transactivation, whereas a truncated REGg-luc construct ( À 738/ þ 130) remained unresponsive to mutant p53 ( Supplementary Fig. S5d ), indicating a cis-element within the ( À 1,177/ À 738) region for mutant p53. To further define the mutant p53-responsive region in the REGg UTR, we generated different REGg-Luc deletion constructs (Fig. 4f) and found that the region between ( À 1,071/ À 969) is essential for mutant p53-dependent transcription (Fig. 4g) . Deletion of this region ( À 1,071/ À 969) abolished the capability of mutant p53 to transactivate the REGg promoter (Fig. 4h) , indicating that sequence from ( À 1,071/ À 969) may be required for mutant p53 binding. ChIP assays were carried out to examine the association of endogenous mutant p53 with this regulatory region. Following immunoprecipitation of chromatin from H1299 p53-R175H stable cell lines transfected with either sip53 or control siRNA, we observed recruitment of mutant p53 to a region flanking ( À 1,144/ À 752) in the REGg UTR, but not in regions 2 kb further upstream or in cells having depleted mutant p53 (Fig. 4i) . We also examined REGg promoter occupancy by naturally occurring mutant p53 with ChIP analysis in human breast cancer and colon cancers cell lines. We detected recruitment of mutant p53 (p53-R280K and p53-R273H) to REGg promoters in MDA-MB-231 and ARO cells (Fig. 4j, upper  two panels) . Interestingly, ChIP analysis also revealed that p300 bound to the REGg promoter in mutant p53 (MDA-MB-231 and ARO)-containing cells but not to cells with depleted mutant p53 (Fig. 4j, lower two panels) . Altogether, our results demonstrate that the REGg-20S proteasome pathway is likely to be a common target for different mutant p53 proteins in multiple human cancer cells and mouse oral cancer cells. Moreover, induction of REGg occurs through recruitment of mutant p53 proteins along with p300 onto the specific regulatory region in REGg UTR. These findings disclose a new regulatory venue for mutant p53-mediated expression of proteasome activator REGg in different cancer cell types.
Mutant p53 prevents Smad3/N-CoR formation on REGc promoter. A previous study showed that mutant p53 attenuates the TGF-b pathway by repressing the TGF-bRII gene, delaying or reducing phosphorylation of Smad2 by TGF-bRI 57 . Because of the negative and positive responses of REGg promoter to TGF-b and mutant p53, respectively, we investigated the effect of TGF-b/ Smad3/4 signalling on REGg expression in mutant p53-expressing cells. We transfected p53-null H1299 cells with Smad3/4 and p53-R175H expression plasmids independently or in combination, and found that mutant p53 was able to attenuate the Smad3/4-mediated inhibition of REGg promoter in fold changes (Fig. 5a ). Furthermore, we also observed a significant reduction in REGg mRNA and protein levels in H1299 control cells when stimulated with TGF-b, whereas this TGF-b-mediated inhibition was alleviated in cells harbouring p53-R175H (Fig. 5b,c) . We obtained similar results in naturally harbouring mutant p53 MDA-MB-231 (p53-R280K) and MDA-MB-1386 (p53-R282W) cells by comparing cells with or without mutant p53 silencing (Fig. 5d,e) . These results prompted us to test the influence of mutant p53 protein on binding of TGF-b-activated Smad3/4 complex to the REGg promoter. For comparison, H1299 cells were infected with a control viral vector, or vectors encoding p53 or p53-R175H, followed by ChIP analysis. We detected the recruitment of Smad3 to REGg promoter in the presence of TGFb in control and p53-expressing cells (Fig. 5f ). Conversely, we observed little binding of Smad3 in p53-R175H-expressing H1299 cells (Fig. 5f, upper panel) . We also validated these observations by ChIP assays in UMSCC-1 cells, stably integrated with an empty vector, p53 or hotspot p53-R175H mutant allele (Fig. 5f , lower panel). We obtained similar results in naturally occurring mutant p53 MDA-MB-231 (Fig. 5g) and stably expressing mutant p53 H1299 cell lines (Fig. 5h) , respectively. In addition, we examined the effect of mutant p53 on Smad3/4-binding affinity to corresponding SBE-4 on the REGg promoter. Nuclear extracts were prepared from H1299 cells co-transfected with Smad3/4, p53 and p53-R175H expression plasmids, alone or in combination (Smad3/4 þ p53 or Smad3/4 þ p53-R175H), followed by TGF-b treatment. We believe the EMSA assay probe containing SBE-4 displayed formation of a Smad3/4-DNA complex, as this complex was strongly enhanced after TGF-b stimulation and attenuated after the addition of Smad antibodies (Fig. 5i, lanes 3 and 10) . Strikingly, the binding capacity of this Smad3/4 complex to the corresponding SBE-4 oligo was completely abolished by mutant p53-R175H (Fig. 5i, lane 9 (Fig. 5j) . We also obtained similar results in MDA-MB-231 breast cancer cells (Fig. 5k) . Consistent with previous report that mutant p53 attenuates the TGF-b pathway, we also found reduced phosphorylation of R-smad ( Supplementary Fig. S6a ). Taken together, these data demonstrate that mutant p53, but not p53, is capable of interrupting TGF-binduced recruitment of Smad complexes to the REGg promoter by attenuating the DNA-binding capacity of Smad3/4 complex to the corresponding SBE. Furthermore, the switch between the recruitment of N-CoR, which promotes histone deacetylation, and that of p300, which should result in increased histone acetylation, provides additional explanation for the transcriptional activation of REGg in mutant p53 harbouring cells in response to TGF-b.
p53 and TGF-b regulate the 20S proteasome pathway via REGc. To understand whether enhanced REGg level correlates with its ability to activate proteasome activity, we measured trypsin-like REGg-20S proteasome activity in multiple human cancer cell lines. To test the effect of p53 on the 20S proteasome activity, we treated A549 cells with ETO and observed that ETO treatment decreased proteasome activity in control cell lines (A549.SHN) but not in REGg-depleted cell lines (A459.SHR; Fig. 6a and Supplementary Fig. S7a ), suggesting that p53 can inhibit the 20S proteasome pathway via REGg. Furthermore, we compared isogenic HCT116p53 þ / þ and HCT116p53 À / À cells, and observed that the 20S proteasome activity was much higher in p53 À / À cells ( Fig. 6b and Supplementary Fig. S7b ), indicating that p53 can regulate the 20S proteasome pathway. Next, we stimulated A549 cells with TGF-b and found that TGFb also repressed the 20S proteasome activity in control cells, but not in REGg-deficient cells (Fig. 6c) . Intriguingly, mutant p53 was able to enhance the proteasome activity (Fig. 6d) . Moreover, we detected lower proteasome activity in REGg knockdown cell lines (ARO.SHR) in the presence of mutant p53, suggesting that mutant p53-induced proteasome activity in ARO cell line depends on REGg expression (Fig. 6e and Supplementary  Fig. S7c ). Strikingly, mutant p53 was able to attenuate the TGF-b-inhibited proteasome pathway in cancer cells, which explains the mutant p53 GOF ability (Fig. 6f) . Expectedly, silencing N-CoR enhanced trypsin-like activity, but not in cells with REGg knockdown cells (Fig. 6g) . Taken together, these data indicate that p53, TGF-b signalling and mutant p53 regulate the 20S proteasome pathway via REGg during cancer progression.
REGc alters cellular response to p53 and TGF-b signalling. Next, we aimed to address the impact of REGg regulation on p53, TGF-b and mutant p53 cellular activities. We treated the A549 cell lines with anticancer drugs and performed cell proliferation assay. We observed that REGg knockdown cell lines showed less resistance to ETO and Adriamycin treatment as compared with control cells (Fig. 7a and Supplementary Fig. S8 ). Thus, depletion of REGg sensitizes cells to genotoxic insults. Furthermore, we measured apoptotic levels by poly (ADP-ribose) polymerase cleavage (an apoptotic marker). We detected significantly more apoptosis in A549 cells than in ARO cells with stable REGg knockdown (Fig. 7b) . Next, we treated A549 cell lines with TGF-b and observed that REGg-depleted cells were more sensitive to TGF-b treatment and were less proliferative in comparison with control cells (Fig. 7c) .
Moreover, overexpression of REGg attenuated the effect of ETO and TGF-b on cell cycle progression, and enhanced S and G2/M phase to accelerate DNA synthesis (Fig. 7d,e and Supplementary Fig. S7e ). Strikingly, REGg decreased p53 protein expression in the presence or absence of ETO, whereas REGg knockdown further enhanced p53 protein levels in ETO-treated cell lines (Fig. 7f,g ), reflecting a regulation of cell cycle progression in a p53-dependent manner. In conclusion, these data show that REGg depletion decreases drug resistance and sensitizes the cancer cells to chemotherapeutic agents. In addition, overexpression of REGg affects the tumour suppressive activities of p53 and TGF-b signalling in cancer cells to enhance cancer progression.
Knockdown of REGc arrests growth and cell cycle progression. Next, we sought to examine the role of REGg on cellular growth and cell cycle transition. To this end, we performed MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in HCT116p53 þ / þ and HCT116p53 À / À cell lines, in which REGg was stably knocked down. Intriguingly, we found that in comparison with REGg-positive HCT116p53 þ / þ cell line, REGg-expressing HCT116p53 À / À cells (SHN) had markedly enhanced cell proliferation. In contrast, REGg knockdown (SHR) cells showed reduced proliferation in both HCT116p53 þ / þ and HCT116p53 À / À cell lines (Fig. 8a) , suggesting that REGg can further enhance cell proliferation in the absence of p53. Intriguingly, REGg knockdown led to inhibition of cell proliferation in ARO (Fig. 8b) and A549 (Fig. 8c) cell lines, suggesting that REGg promotes cell viability. Next, we assessed the proliferative role of REGg and mutant p53 in breast cancer cell lines. Importantly, knockdown of REGg and mutant p53 independently decreased cell growth (Fig. 8d and Supplementary  Figs S7d and S9) . Strikingly, cosilencing of mutant p53 and REGg further inhibited cell proliferation in breast cancer cell lines (Fig. 8d) . These data indicate that REGg has an important role in cell proliferation of these cancer cell lines in response to p53 signalling.
Next, we aimed to examine the effect of REGg on cell cycle progression in cancer cell lines. Fluorescence-activated cell sorting analyses showed that overexpression of REGg enhanced the S (DNA synthesis) and G2/M (mitotic) phase (Fig. 8e) . Conversely, depletion of REGg attenuated transition of G0/G1 cells to S and G2/M phases, which are important for cell growth (Fig. 8f-h ). These data indicate that REGg promotes cell growth via enhancing DNA synthesis in cancer cells.
REGc expression correlates with mutant p53 in cancer tissues. Next, we examined REGg expression in several human cancer cell lines. In contrast to p53-expressing cancer cell lines, we observed higher expression of REGg in mutant p53-expressing cells (Fig. 9a, left panel) . Importantly, western blot analysis also showed higher level of REGg in Smad4-null cells. However, cancer cell lines expressing Smad4 had reduced level of REGg (Fig. 9a, right panel) . We observed similar results by analysing REGg transcript in these cancer cell lines (Fig. 9b,c) .
To further understand the biological relevance of our findings discussed above in tumour development, we evaluated the correlation between REGg and mutant p53 expression by immunohistochemistry (IHC) analysis of 101 human cancer tissues. We detected a higher percentage of REGg-positive rates in specimens with p53 overexpression compared with p53-negative groups, suggesting a positive correlation of mutant p53 with REGg (Fig. 9d) . The statistical analysis between REGg and mutant p53 is shown in Fig. 9e and Supplementary Fig. S10a . We analysed the correlation between REGg and mutant p53 from the same sets of tumours by scatter and agreement plots. These plots indicated that these two proteins are highly associated with each other in the same sets as that of the tumours (Fig. 9f and Supplementary Fig. S10b) .
Furthermore, we performed bioinformatic analysis to check the effect of REGg overexpression on p53/TGF-b signalling ARTICLE pathway using previously collected data sets (GSE10972, GSE4183, GSE8671, GSE10072, GSE4115 and GSE7670) 14 from the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/). Intriguingly, we found that higher expression of REGg is correlated with a low level of p53, TGF-b RI, TGF-b RII and TGF-b RIII gene expressions (Fig. 9g) , further implicating regulatory roles of p53/TGF-b in controlling REGg and cancer development.
Discussion
In this report, we investigated the previously unknown mechanism for regulation of the REGg-20S proteasome pathway in cancer cells during tumour development. This study indicates differential regulation of REGg-20S proteasome pathway by p53/ TGF-b signalling and mutant p53 proteins via REGg in tumour cells. Our results provide the first example that anomaly in p53/TGF-b tumour suppressive signalling deregulates REGgmediated ubiquitin/ATP-independent proteasome pathway during tumorigenesis (Fig. 10a) . REGg has been found to promote degradation of p53 by acting as a coactivator to promote MDM2-mediated p53 ubiquitination. Depletion of REGg has been shown to lead to increased p53 protein levels in several cancer cell lines. Together with previous findings, the present study provides a previously unknown model, in which an autoregulatory feedback loop exists between p53 and REGg. We believe that when p53 is elevated to elicit its biological functions, such as apoptosis, the activity of the REGg-proteasome pathway will be inhibited to avoid p53 degradation and cell proliferative effects. It is generally believed that the Smad-dependent pathway is involved in TGF-b tumour suppressive functions, whereas activation of Smad-independent pathways is coupled with loss of tumour suppressor function of TGF-b, which is important for its pro-oncogenic effects. Elevated expression of REGg in both colonic adenoma and invasive cancers suggest that REGg may have important roles during carcinogenesis. GOF effects of mutant p53 is associated with poor prognosis in cancers. In this study, we show that mutation of p53 enhances REGg transcription in breast and colon cancer cells. In addition, mutant p53 antagonizes Smad-dependent inhibition of REGg expression in response to TGF-b by preventing the recruitment of the Smad/N-CoR complex. The accumulated mutant p53 can function as an activator of the REGg-20S proteasome pathway. Strikingly, mutant p53 recruits p300 on one hand and, on another hand, blocks Smad protein binding. These findings suggest a novel bipartite mechanism by which mutant p53 reprogrammes transcriptional activation of proteasome activator in cancer cells (Fig. 10b) .
Our study highlights the link between p53/TGF-b signalling and the 20S proteasome pathway via REGg. Our results indicate that both p53 and TGF-b/Smad signalling can inhibit the REGg-20S proteasome pathway to prevent degradation of important tumour suppressor proteins such as p53/p21/p16. Our data also suggest that REGg-expressing cells are more resistant to anti-cancer drugs, and knockdown of REGg decreases chemoresistance in cancer cells. Importantly, we also show that REGg can attenuate the antiproliferative function of TGF-b/Smad signalling. The opposite behaviour of REGg in cell proliferation and cell cycle regulation upon silencing p53 or mutant p53 reflect the differential response to distinct p53 signalling and further validate the regulatory mechanisms. Intriguingly, our data also suggest that overexpression of REGg accelerates DNA synthesis via enhancing S and G2/M phase during tumour development.
Strikingly, our IHC analyses show a positive correlation between mutant p53 and REGg in the rectum, gastric, renal, ovary and colon cancer tissues. Similarly, Smad4-null breast cancer cell lines reveal higher expression of REGg. Importantly, these analyses indicate that targeting the REGg-20S proteasome pathway for cancer therapy may be helpful for human tumours having abnormal Smad/p53 proteins status. In addition to this, our bioinformatics data also show that overexpression of REGg in lung and colon cancer tissues negatively regulates tumour suppressive p53 and TGF-b signalling. Before our studies, no satisfactory mechanism has been proposed for the REGg-20S proteasome pathway regulation during cancer progression, even though growing evidence suggests that the REGg-20S proteasome pathway is involved in cancer progression. For cell treatments, we used 5 ng ml À 1 TGF-b1 (R&D), 10 mmol l À 1 Nutlin-3a (Sigma-Aldrich), 5 mg ml À 1 cisplatin (Sigma-Aldrich) and (10 mmol) ETO (Sigma-Aldrich).
Electrophoretic mobility shift assay. EMSA assay was performed with 32 P-radiolabelled probes. Two micrograms of nuclear extract or different concentrations of purified proteins was incubated with 32 P-radiolabelled probes in 20 ml of EMSA assay reaction buffer (2 mg of poly (dI-dC), 20 mM HEPES (pH 7.9), 1 mM MgCl 2 , 40 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol (DTT) and 12% glycerol). To perform the competition assay, excess of unlabelled competitor's oligo was added to the EMSA assay reaction mixture. Protein-DNA complexes were resolved in 5% polyacrylamide gels containing 0.5 Â Tris-Borate-EDTA (TBE) and exposed to a phoshoimager (Bio-Rad). For the supershift assay, nuclear extracts in the EMSA assay reaction buffer were incubated with different antibodies for 30 min and probes were then added. Probe sequences are described in Supplementary  Table S1 .
ChIP assay. After treatment with TGF-b/Nutlin-3, nuclear proteins were crosslinked to genomic DNA by adding formaldehyde for 10 min directly to the medium to a final concentration of 1%. Crosslinking was stopped by adding glycine to a final concentration of 0.125 M and incubating for 5 min at room temperature on a rocking platform. The medium was removed and the cells were washed twice with ice-cold PBS (140 mM NaCl, 2.7 mM KCl, 1.5 mM KH 2 PO 4 and 8.1 mM Na 2 H-PO 4 Á 2H 2 O). The cells were collected by scraping in ice-cold PBS supplemented with a protease inhibitor cocktail. After centrifugation, the cell pellets were resuspended in lysis buffer (1% SDS, 10 mM EDTA, protease inhibitors and 50 mM Tris-HCl (pH 8.1)) and the lysates were sonicated to result in DNA fragments of B200-1,000 bp in length. Cellular debris was removed by centrifugation and the lysates were diluted 1:10 in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM NaCl, protease inhibitors and 16.7 mM Tris-HCl (pH 8.1)). Nonspecific background was removed by incubating the chromatin resuspension with a salmon sperm DNA/protein A agarose slurry for 30 min at 4°C with agitation. The samples were centrifuged and the recovered chromatin solutions were incubated with 3-5 mg of indicated antibodies overnight at 4°C with rotation. The immunocomplexes were collected with 60 ml of protein A agarose slurry for 2 h at 4°C with rotation. The beads were pelleted by centrifugation for 1 min at 4°C and washed sequentially for 5 min by rotation with 1 ml of the following buffers: low-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl and 20 mM Tris-HCl (pH 8.1)), high-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl and 20 mM Tris-HCl (pH 8.1)) and LiCl wash buffer (0.25 mM LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA and 10 mM Tris-HCl (pH 8.1)). Finally, the beads were washed twice with 1 ml TE buffer (1 mM EDTA and 10 mM Tris-HCl (pH 8.0)). The immunocomplexes were then eluted by adding 250 ml elution buffer (1% SDS and 100 mM NaHCO 3 ) and incubated for 15 min at room temperature with rotation. After centrifugation, the supernatant was collected and the crosslinking was reversed by adding NaCl to a final concentration of 200 mM and incubating overnight at 65°C. The remaining proteins were digested by adding proteinase K (final concentration 40 mg ml À 1 ) and incubation for 1 h at 45°C. using glycogen as a carrier. PCR amplification of the genomic fragments was performed with specific primers flanking putative binding sites on the REGg promoter. The PCR products were separated by electrophoresis through 2.0% agarose. The primer sequences are described in Supplementary Table S2 .
Immunohistochemistry. Paraffin-embedded sections (3 mm thick) of different tumours and adjacent normal tissues were used to perform IHC reaction. Tissue sections were deparaffined with xylene and dehydrated with sequential washes of 100, 95 and 70% ethanol. Endogenous peroxidase activity was quenched using 0.3% hydrogen peroxide in methanol for 30 min and then washed in PBS. Antigen retrieval was achieved using a pressure boiler heating in retrieval solution, pH 6, at 125°C for 4 min, followed by a 20-min cool-down period at room temperature. Slides were then incubated with anti-p53 antibody (1:300) dilutions and anti-REGg antibody (1:500) dilutions at 4°C overnight. Next, the slides were rinsed three times in PBS and incubated in biotin-labelled rabbit antirabbit secondary antibodies for 1 h at room temperature. After washing three times with PBS, the staining was performed using 3, 3 0 -diaminobenzidine. Sections were counterstained with haematoxylin and the staining intensity was evaluated on a scale of 0-2, and was rated as negative ( À ), weak staining ( þ ), moderate/strong staining ( þ þ ) and very strong staining ( þ þ þ ). We also compared IHC data between tumours and corresponding adjacent normal tissues by percentage of intensity of staining to estimate the changes of REGg expression.
Production and purification of Smad and p53 fusion proteins. Full-length Smad3/Smad4 and p53 proteins fused to glutathione S-transferase were expressed in Escherichia coli and were partially purified by column chromatography using Pharmacia's protocol. Briefly, bacteria were grown in 2 Â YTA medium and induced with 0.1 mM isopropyl-b-D-thiogalactoside. After sonication, glutathione S-transferase fusions were isolated using glutathione Sepharose 4B, washed three times, eluted and then dialysed against PBS supplemented with 2 mM DTT and 0.5 mM phenylmethylsulphonyl fluoride (PMSF).
REGc luciferase reporter constructs. DNA fragments containing REGg genomic sequences were amplified from 293T cell genomic DNA using PCR, and primers were derived from human genomic REGg and ligated into kpn1/xhol sites of the promoterless pGL3-Basic (Promega, Madison, USA) vector and was named as pGL3-REGg-luc. Different deletion constructs of the REGg promoter were generated from 1.3 kb REGg promoter and ligated into kpn1/xhol sites of the pGL3-Basic vector.
Luciferase assay. After transfection and/or treatment, the cells were washed with PBS three times. The cells were then lysed in the luciferase cell culture lysis buffer provided with the Luciferase Assay Kit (Promega). After a brief vortexing, wholecell lysates were centrifuged in the cold (4°C) at 13,000g for 2 min. Supernatant was collected in a fresh tube and 20-30 ml of it was added to the luciferase assay substrate (60-80 ml). Luminescence was measured as relative light units, twice for each lysate, taking the reading of luciferase assay using a LUMIstar OPTIMA (BMG Labtech). Each assay was repeated for three times. Fold repression values were represented as mean of the three experiments.
Nuclear extract preparation. Cells from 100-mm dishes were washed with PBS and scraped. After another washing, cells were suspended in 2 ml of cold buffer A (20 mM HEPES, pH 7.9, 20 mM NaF, 1 mM Na 3 VO 4 , 1 mM Na 4 P 2 O 7 , 0.13 mM okadaic acid, 1 mM EDTA, 1 mM EGTA, 0.4 mM ammonium molybdate, 1 mM DTT, 0.5 mM PMSF and 1 mg ml À 1 each of leupeptin, aprotinin and pepstatin). Cells were allowed to swell on ice for 15 min and then lysed by 30 strokes of a Dounce all-glass homogenizer. Nuclei were pelleted by centrifugation and resuspended in 600 ml of cold buffer C (buffer A, 420 mM NaCl and 20% glycerol). The nucleus membrane was lysed by 15 strokes of a Dounce all-glass homogenizer. The resulting suspension was stirred for 30 min at 4°C. The clear supernatant was aliquoted and frozen at À 80°C.
RNA interference. Cells were cultured to 30% confluence. For each well in a 6-well culture dish, 20 nM of Smad3/p53 siRNAs or appropriate negative controls siRNAs was transfected into cells using Lipofectamine 2000 (Invitrogen) following manufacturer's protocol. Cells were incubated at 37°C in a CO 2 incubator and, after 6-8 h, 10% serum growth medium was added to the transfection mixture. Cell extracts were assayed by western blotting for Smad3/p53 protein expression at 72 h post transfection, whereas at 48 h after transfection for mRNA expression. The primer sequences are described in Supplementary Table S3 .
Reverse transcriptase-PCR. Total RNA from cells was isolated using TRIZOL (Invitrogen), following the manufacturer's protocol. Briefly, 0.5-1 mg of total RNA was reverse-transcribed in a total volume of 25 ml, including 132 units of Moloneymurine-leukemia virus reverse transcriptase, 26.4 units of RNAase inhibitor, 0.6 mg of (dT)15 primer, 2 mM dNTPs and 1 Â Moloney-murine-leukemia virus Reverse transcriptase (RT) buffer provided by Promega. Aliquots of the RT products were used for RT-PCR analysis. For semiquantitative RT-PCR analysis, 2 ml of RT products were brought to a volume of 25 ml containing 1.5 mM MgCl 2 , 0.25 mM of each dNTPs, 0.5 mM of both the upstream and downstream PCR primers and 1 Â Taq reaction buffer and 1.25 units of Taq DNA polymerase, provided by Promega. PCR products were visualized by electrophoresis on a 2% agarose gel in 0.5 Â Trisborate-EDTA (TBE) buffer after staining with 0.5 mg ml À 1 ethidium bromide. For quantitative RT-PCR analysis, 2 ml of reverse-transcribed cDNA was subjected to RT-PCR using mastermix with SYBR-green (Bio-Rad) and the Mx3005P-quantitative RT-PCR system (Stratagene). Each reaction consisted SYBR-green (1:60,000 final concentration), 40 nM of both sense and antisense primers, 2 ml of cDNA and H 2 O to a final volume of 20 ml. Each experiment was performed in duplicates and was repeated three times. Primer sequences are described in Supplementary  Table S4 .
Preparation of total cell extract and western blot analysis. Cells were washed with PBS and treated with an extraction buffer (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl and 1 mM EDTA) supplemented with 1 mM PMSF, 1 mM sodium orthovanadate (Na 3 VO 4 ), 0.1 mM DTT, 0.4 mg ml À 1 leupeptin/ pepstatin). Cell extract was stored at À 20°C until required. Protein samples were subject to electrophoresis in 10% SDS-PAGE. Separated proteins were electroblotted to nitrocellulose membranes (Bio-Rad), and the blot was blocked for 1 h at room temperature with blocking buffer (0.1% PBS with Tween-20 with 5% fat-free, dried milk powder). The blot was then incubated with primary antibodies, (1:1,000 dilutions) at 4°C overnight. The blot was washed three times with 0.1% Tris-buffered saline with Tween-20 and incubated with secondary antibodies (mouse, rabbit; 1:5,000 dilution) for 1 h. The blot was washed again three times and exposed to Odyssey LI-COR-scanner. The full-length membranes are shown in Supplementary Figs S11-S18.
MTT assay. Cell viability was assessed with an MTT assay in replicates. Cells were seeded in 96-well plates at 2.5 Â 10 3 cells per well and incubated in 10% fetal bovine serum supplemented with DMEM for 24 h. After that, cells were treated with ETO/TGF-b for indicated time points. Controls received dimethylsulphoxide vehicle at a concentration equal to that in drug-treated cells. Next, drug-containing medium was replaced with 200 ml of 10% fetal bovine serum supplemented with DMEM containing 0.5 mg ml À 1 MTT, and cells were incubated in the CO 2 incubator at 37°C for 2 h and absorbance (490 nm) was measured and analysed.
Cell cycle analysis. Cell cycle analysis was carried out estimating DNA contents with flow cytometry. Cells were fixed in ice-cold 70% ethanol, incubated overnight at À 20°C and stained with propidium iodide/Triton X-100 containing RNaseA solution for 15 min at 37°C. Cell cycle analysis was performed using BD CantoII cell analyser.
